Evidence map›Paper›PMID 24141789›Full record

ArticleOncogene2014

FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance.

P Khongkow, U Karunarathna, M Khongkow, C Gong, A R Gomes, E Yagüe, L J Monteiro, M Kongsema, S Zona, E P S Man and 7 more

Open access · hybridAbstract read
In one paragraph

Article in Oncogene, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 1 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 1 synthesis or guideline pooled it, 133 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Genes as Genome Stabilizers in Pluripotent Stem Cells.Advances in experimental medicine and biology · 2025
    Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Interruptin C, a Radioprotective Agent, Derived fromMolecules (Basel, Switzerland) · 2022
    Article
  20. Article

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 6 countries.

P KhongkowDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK.
U KarunarathnaDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK.
M KhongkowDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK.
C Gong1] Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK [2] Department of Pathology, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.
A R GomesDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK.
E YagüeDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK.
L J MonteiroDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK.
M KongsemaDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK.
S ZonaDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK.
E P S ManDepartment of Pathology, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.
J W-H TsangDepartment of Clinical Oncology, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.
R C CoombesDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK.
K-J WuInstitute of Biochemistry and Molecular Biology, National Yang-Ming University, Taipei 112, Taiwan.
U-S KhooDepartment of Pathology, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.
R H MedemaDivision of Cell Biology, the Netherlands Cancer Institute, Amsterdam, The Netherlands.
R FreireUnidad de Investigación, Hospital Universitario de Canarias, Instituto de Tecnologías Biomédicas, Ofra s/n, La Laguna, Spain.
E W-F LamDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK.
Hammersmith Hospital · GBImperial College London · GBUniversity of Hong Kong · HKChinese University of Hong Kong · CNHospital Universitario de Canarias · ESNational Yang Ming Chiao Tung University · TWThe Netherlands Cancer Institute · NL

Funding

Breast Cancer Now 2012MAYPR070Breast Cancer Now 2012NOVPHD016Cancer Research UK 12011Cancer Research UK A12011
6 · The paper itself

Abstract

FOXM1 is implicated in genotoxic drug resistance but its mechanism of action remains elusive. We show here that FOXM1-depletion can sensitize breast cancer cells and mouse embryonic fibroblasts (MEFs) into entering epirubicin-induced senescence, with the loss of long-term cell proliferation ability, the accumulation of γH2AX foci, and the induction of senescence-associated β-galactosidase activity and cell morphology. Conversely, reconstitution of FOXM1 in FOXM1-deficient MEFs alleviates the accumulation of senescence-associated γH2AX foci. We also demonstrate that FOXM1 regulates NBS1 at the transcriptional level through an forkhead response element on its promoter. Like FOXM1, NBS1 is overexpressed in the epirubicin-resistant MCF-7Epi(R) cells and its expression level is low but inducible by epirubicin in MCF-7 cells. Consistently, overexpression of FOXM1 augmented and FOXM1 depletion reduced NBS1 expression and epirubicin-induced ataxia-telangiectasia mutated (ATM)phosphorylation in breast cancer cells. Together these findings suggest that FOXM1 increases NBS1 expression and ATM phosphorylation, possibly through increasing the levels of the MRN(MRE11/RAD50/NBS1) complex. Consistent with this idea, the loss of P-ATM induction by epirubicin in the NBS1-deficient NBS1-LBI fibroblasts can be rescued by NBS1 reconstitution. Resembling FOXM1, NBS1 depletion also rendered MCF-7 and MCF-7Epi(R) cells more sensitive to epirubicin-induced cellular senescence. In agreement, the DNA repair-defective and senescence phenotypes in FOXM1-deficent cells can be effectively rescued by overexpression of NBS1. Moreover, overexpression of NBS1 and FOXM1 similarly enhanced and their depletion downregulated homologous recombination (HR) DNA repair activity. Crucially, overexpression of FOXM1 failed to augment HR activity in the background of NBS1 depletion, demonstrating that NBS1 is indispensable for the HR function of FOXM1. The physiological relevance of the regulation of NBS1 expression by FOXM1 is further underscored by the strong and significant correlation between nuclear FOXM1 and total NBS1 expression in breast cancer patient samples, further suggesting that NBS1 as a key FOXM1 target gene involved in DNA damage response, genotoxic drug resistance and DNA damage-induced senescence.

Indexed as

Cellular SenescenceDNA DamageDrug Resistance, NeoplasmAnimalsAntibiotics, AntineoplasticCell Cycle ProteinsDNA-Binding ProteinsDNA RepairEpirubicinFibroblastsForkhead Box Protein M1Forkhead Transcription FactorsGene DeletionGene Expression Regulation, NeoplasticGene SilencingHumansAntibiotics, AntineoplasticCell Cycle ProteinsDNA-Binding ProteinsEpirubicinForkhead Box Protein M1Forkhead Transcription FactorsFOXM1 protein, humanFoxm1 protein, mouseNBN protein, humanNijmegen breakage syndrome 1 protein, mouseNuclear Proteins

Identifiers

PMID24141789
PMCPMC3969838
OpenAlexW2028748220

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.